Policlinico Le Scotte
- Address
- Viale Mario Bracci 16, 53100 Siena, Italy
Cardiovascular Diseases
At Policlinico Le Scotte in Siena, the cardiovascular research program focuses on chronic heart failure with reduced ejection fraction, with trials designed to assess whether new treatment approaches can better lower the risk of heart-related hospitalizations and cardiovascular death.
- Improving treatment effectiveness in heart failure
- Evaluating a therapy aimed at reducing major cardiovascular events
- Studying outcomes that matter most to patients with advanced heart disease
This area reflects a strong interest in practical, outcome-driven research for people living with serious cardiovascular disease.
Neoplasms
The site is also active in oncology, with clinical trials spanning several solid tumors such as melanoma, lung cancer, and other advanced cancers. These studies are mainly aimed at testing new therapies, comparing them with established treatments, and understanding which patients may benefit most.
- Research in advanced solid tumors
- Studies in melanoma and other cancer types
- Evaluating treatment response and long-term benefit
There is also work on ongoing access and continued treatment for people already benefiting from pemigatinib, highlighting the site’s role in supporting patients with complex malignancies.
Skin and Connective Tissue Diseases
Research in skin and connective tissue diseases includes studies on chronic spontaneous urticaria and melanoma, showing a mix of inflammatory and cancer-related dermatologic research. The trials are designed to improve symptom control, assess treatment effectiveness, and support better disease management.
- Clinical research in chronic spontaneous urticaria
- Investigations involving melanoma
- Assessing relief of symptoms and overall disease control
These studies add a valuable dermatology-focused dimension to the clinical trial portfolio at Policlinico Le Scotte.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Merck Sharp & Dohme LLC1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC4trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Policlinico Le Scotte
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE-158) | Merck Sharp & Dohme LLC | Phase II | Not Recruiting | Feb 2016 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 3 | Unknown | 2016-02-02 | 2023-08-01 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.